Clinical trial
Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma…
NCT00002458 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002458 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission |
| Official title | Phase II Study of Adjuvant Therapy With Antiganglioside GD2-Specific Mouse Monoclonal Antibody 3F8 for Metastatic Neuroblastoma in Second Remission |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | monoclonal antibody 3F8 |
| Start date | Nov 1, 1987 |
| Primary completion | Sep 1, 2001 |
| Completion | Sep 1, 2001 |
| First posted | Aug 30, 2004 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: